Artios Banks On DNA Repair To Challenge IO Space

 
• By Mike Ward

With a better understanding of how DNA damage repair (DDR) pathways operate in cancer cells, UK biotech Artios Pharma, in partnership with Cancer Research UK, is looking to develop drug candidates that can selectively kill tumor cells. Speaking at the Biotech Showcase 2018, Artios CEO Niall Martin told Scrip how the company is advancing its lead programs towards the clinic and is seeking series B venture capital to demonstrate proof of concept for the lead programs.  

Video interview

Cancers change their DDR pathways to allow mutations in their DNA so that they can evolve and adapt enabling them to become resistant to current therapies. Targeting the DDR has been clinically validated through the recent success of PARP.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas